Latest Pharma and Biotech News
Pharmaceutical
17 June 2026 US pharma major Eli Lilly has acquired 4E Therapeutics, adding a pipeline of oral MNK inhibitors designed to treat chronic pain without the central nervous system effects linked to many existing therapies.
Today's issue
Refine search
Pharmaceutical
GSK and Spero Therapeutics today announced that the US Food and Drug Administration (FDA) has approved Utebzi (tebipenem pivoxil), an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs). 17 June 2026
Pharmaceutical
Biopharma dealmaking strengthened sharply at the start of 2026, as large drugmakers moved to replenish pipelines ahead of looming patent expiries, according to PwC’s Pharmaceutical and life sciences: US Deals 2026 midyear outlook. 17 June 2026
Biotechnology
Ireland-headquartered Jazz Pharmaceuticals and Canada’s AbCellera today announced a pre-clinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. 17 June 2026
Biotechnology
The radiopharmaceutical sector has remained one of biotech’s hottest areas over the past two years, attracting billions of dollars in investment, partnerships and acquisitions. But according to Leila Jaafar, chief executive of Swiss radiopharma developer Nuclidium, the debate is becoming more nuanced. 17 June 2026
Pharmaceutical
New data published in Brain Communications offers a strong picture of how devastating thymidine kinase 2 deficiency (TK2d) can be without treatment - and how vital earlier diagnosis and treatment are in potentially changing the course of disease. 17 June 2026
Biotechnology
US biotech Vedana Therapeutics, which is developing next-generation therapies for migraine prevention, today emerged from stealth with $46 million in Series A financing. 17 June 2026
Biotechnology
German neuroscience company HMNC Brain Health has appointed former Lundbeck executive Bjørn Grønning as chief medical officer as it prepares two depression programs for Phase III-readiness activities. 17 June 2026
Pharmaceutical
Japanese pharma major Daiichi Sankyo announced that its Vanflyta (quizartinib) has been approved in China for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation. 17 June 2026
Biotechnology
Shares in US biotech Edgewise Therapeutics closed 3.6% lower at $33.95 on Tuesday, after a volatile session in which investors weighed positive Phase II data for its hypertrophic cardiomyopathy (HCM) candidate EDG-7500 against already high expectations for the program. 17 June 2026
Biotechnology
Moderna faces a key US Food and Drug Administration (FDA) advisory committee meeting this week for MFLUSIVA (mRNA-1010), its investigational mRNA-based seasonal influenza vaccine. 17 June 2026
Biosimilars
Switzerland-based Sandoz, a leader in affordable medicines, today inaugurated a new biosimilar development center in Ljubljana, Slovenia, to strengthen and expand its in house biosimilar capabilities. 17 June 2026
Biotechnology
Polish biotech Mabion has signed a letter of intent with French TechDev company Oddifact to explore MabionCD20 in rare diseases, reopening a program that was once developed as a rituximab biosimilar. 17 June 2026
Pharmaceutical
US pharma major Eli Lilly has acquired 4E Therapeutics, adding a pipeline of oral MNK inhibitors designed to treat chronic pain without the central nervous system effects linked to many existing therapies. 17 June 2026
Biotechnology
The microbiome sector has approved medicines on the market, but it has not yet delivered the broad therapeutic class that early investors once expected. Its current phase is more focused, with companies trying to show that gut bacteria can be developed into consistent, regulated products with clear clinical uses. 17 June 2026
Biotechnology
Outlook Therapeutics shares climbed more than 25% to $1.46 on Tuesday, after the company said the US Food and Drug Administration (FDA) has accepted its resubmitted biologics license application (BLA) for ONS-5010/Lytenava as a treatment for age-related macular degeneration (AMD), a condition in which retina damage results in vision loss. 17 June 2026
Pharmaceutical
Public Citizen, Health Global Access Project, and eight organizations sent a letter to the US Biomedical Advanced Research and Development Authority (BARDA) within the Department of Health and Human Services urging the US government to share candidate Ebola Bundibugyo therapeutics that it has in its possession and coordinate with the World Health Organization, Africa CDC, affected-country governments, medical humanitarian organizations and international and civil society to address current and future outbreaks. 17 June 2026
Biotechnology
US biotech Protillion Biosciences has entered a multi-target discovery collaboration and license agreement with pharma major Merck & Co. 16 June 2026
Biotechnology
Moderna today announced changes to its operating model to support its short- and long-term business goals, with the news sending the US mRNA vaccines firm’s shares up 3.5% to $53.97 by mid-morning. 16 June 2026
Generics
India is grappling with a severe shortage of two cornerstone chemotherapy drugs, cisplatin and carboplatin, as soaring platinum prices, higher import duties, and regulatory delays make production financially unsustainable. 16 June 2026
Biotechnology
San Diego, USA-based Soleno Therapeutics, which has just been acquired by Neurocrine Biosciences, has announced late-breaking data at ENDO 2026 showing that resuming treatment with Vykat XR (diazoxide choline) extended-release tablets . 16 June 2026
All news
Pharmaceutical
GSK and Spero Therapeutics today announced that the US Food and Drug Administration (FDA) has approved Utebzi (tebipenem pivoxil), an oral antibiotic for the treatment of complicated urinary tract infections (cUTIs). 17 June 2026
Pharmaceutical
Biopharma dealmaking strengthened sharply at the start of 2026, as large drugmakers moved to replenish pipelines ahead of looming patent expiries, according to PwC’s Pharmaceutical and life sciences: US Deals 2026 midyear outlook. 17 June 2026
Biotechnology
Ireland-headquartered Jazz Pharmaceuticals and Canada’s AbCellera today announced a pre-clinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. 17 June 2026
Biotechnology
The radiopharmaceutical sector has remained one of biotech’s hottest areas over the past two years, attracting billions of dollars in investment, partnerships and acquisitions. But according to Leila Jaafar, chief executive of Swiss radiopharma developer Nuclidium, the debate is becoming more nuanced. 17 June 2026
Pharmaceutical
New data published in Brain Communications offers a strong picture of how devastating thymidine kinase 2 deficiency (TK2d) can be without treatment - and how vital earlier diagnosis and treatment are in potentially changing the course of disease. 17 June 2026
Biotechnology
US biotech Vedana Therapeutics, which is developing next-generation therapies for migraine prevention, today emerged from stealth with $46 million in Series A financing. 17 June 2026
Biotechnology
German neuroscience company HMNC Brain Health has appointed former Lundbeck executive Bjørn Grønning as chief medical officer as it prepares two depression programs for Phase III-readiness activities. 17 June 2026
Pharmaceutical
Japanese pharma major Daiichi Sankyo announced that its Vanflyta (quizartinib) has been approved in China for use in combination with standard cytarabine and anthracycline induction and cytarabine consolidation. 17 June 2026
Biotechnology
Shares in US biotech Edgewise Therapeutics closed 3.6% lower at $33.95 on Tuesday, after a volatile session in which investors weighed positive Phase II data for its hypertrophic cardiomyopathy (HCM) candidate EDG-7500 against already high expectations for the program. 17 June 2026
Biotechnology
Moderna faces a key US Food and Drug Administration (FDA) advisory committee meeting this week for MFLUSIVA (mRNA-1010), its investigational mRNA-based seasonal influenza vaccine. 17 June 2026
Biosimilars
Switzerland-based Sandoz, a leader in affordable medicines, today inaugurated a new biosimilar development center in Ljubljana, Slovenia, to strengthen and expand its in house biosimilar capabilities. 17 June 2026
Biotechnology
Polish biotech Mabion has signed a letter of intent with French TechDev company Oddifact to explore MabionCD20 in rare diseases, reopening a program that was once developed as a rituximab biosimilar. 17 June 2026
Pharmaceutical
US pharma major Eli Lilly has acquired 4E Therapeutics, adding a pipeline of oral MNK inhibitors designed to treat chronic pain without the central nervous system effects linked to many existing therapies. 17 June 2026
Biotechnology
The microbiome sector has approved medicines on the market, but it has not yet delivered the broad therapeutic class that early investors once expected. Its current phase is more focused, with companies trying to show that gut bacteria can be developed into consistent, regulated products with clear clinical uses. 17 June 2026
Biotechnology
Outlook Therapeutics shares climbed more than 25% to $1.46 on Tuesday, after the company said the US Food and Drug Administration (FDA) has accepted its resubmitted biologics license application (BLA) for ONS-5010/Lytenava as a treatment for age-related macular degeneration (AMD), a condition in which retina damage results in vision loss. 17 June 2026
Pharmaceutical
Public Citizen, Health Global Access Project, and eight organizations sent a letter to the US Biomedical Advanced Research and Development Authority (BARDA) within the Department of Health and Human Services urging the US government to share candidate Ebola Bundibugyo therapeutics that it has in its possession and coordinate with the World Health Organization, Africa CDC, affected-country governments, medical humanitarian organizations and international and civil society to address current and future outbreaks. 17 June 2026
Biotechnology
US biotech Protillion Biosciences has entered a multi-target discovery collaboration and license agreement with pharma major Merck & Co. 16 June 2026
Biotechnology
Moderna today announced changes to its operating model to support its short- and long-term business goals, with the news sending the US mRNA vaccines firm’s shares up 3.5% to $53.97 by mid-morning. 16 June 2026
Generics
India is grappling with a severe shortage of two cornerstone chemotherapy drugs, cisplatin and carboplatin, as soaring platinum prices, higher import duties, and regulatory delays make production financially unsustainable. 16 June 2026
Biotechnology
San Diego, USA-based Soleno Therapeutics, which has just been acquired by Neurocrine Biosciences, has announced late-breaking data at ENDO 2026 showing that resuming treatment with Vykat XR (diazoxide choline) extended-release tablets . 16 June 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze